Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:5.99.1.2 (
topoisomerase
)
9,166
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tissue inhibitor of metalloproteinase 1
(
TIMP-1
) is a protein with a potential biological role in drug resistance. To elucidate the unknown molecular mechanisms underlying the association between high
TIMP-1
levels and increased chemotherapy resistance, we employed SILAC-based quantitative mass spectrometry to analyze global proteome and phosphoproteome differences of MCF-7 breast cancer cells expressing high or low levels of
TIMP-1
. In
TIMP-1
high expressing cells, 312 proteins and 452 phosphorylation sites were up-regulated. Among these were the cancer drug targets
topoisomerase
1, 2A, and 2B, which may explain the resistance phenotype to
topoisomerase
inhibitors that was observed in cells with high
TIMP-1
levels. Pathway analysis showed an enrichment of proteins from functional categories such as apoptosis, cell cycle, DNA repair, transcription factors, drug targets and proteins associated with drug resistance or sensitivity, and drug transportation. The NetworKIN algorithm predicted the protein kinases CK2a, CDK1, PLK1, and ATM as likely candidates involved in the hyperphosphorylation of the topoisomerases. Up-regulation of protein and/or phosphorylation levels of topoisomerases in
TIMP-1
high expressing cells may be part of the mechanisms by which
TIMP-1
confers resistance to treatment with the widely used
topoisomerase
inhibitors in breast and colorectal cancer.
...
PMID:TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. 2390 92